ACC 2018 | SECURE-PCI: High Dose of Statins pior PCI Could Help

Patients undergoing acute coronary syndrome (ACS) loaded with a high dose of statins prior diagnostic catheterization do not seem to benefit from this strategy.

ACC 2018 | SECURE-PCI: Altas dosis de estatinas previo a la angioplastia podrían ayudarHowever, when looking at those undergoing PCI alone (excluding all patients who had received surgery or medical treatment), the benefit appears as a reduction of combined major events. The benefit of atorvastatin loading prior procedure seems to be driven by a reduction of unrelated MI.

The SECURE-PCI, presented at ACC 2018 scientific sessions and simultaneously published by JAMA, should be interpreted globally as a negative study where favorable outcomes were observed only in a subgroup of patients. Even though this has been prespecified in the protocol, it should be regarded as no more than a hypothesis generator.


Read also: ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding.


Outcomes are consistent with other small study outcomes and this benefit seems logical, especially in patients undergoing ACS.

Studies such as the PROVE-IT and the IMPROVE-IT have shown the benefit of intensive care with statins within 7 days after ACS in PCI patients. The present study reduces this benefit even more and starts treatment before revascularization. We could challenge the benefit of this course of action but the fact that there were no adverse effects puts us at ease.

The SECURE-PCI was carried out in 53 centers in Brazil and randomized 4191 patients undergoing ACS assessed with angiography to receive 80mg load of atorvastatin vs placebo prior PCI and 24 hrs. after PCI. Both branches continued with 40 mg atorvastatin after the second dose of medication.


Read also: ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS.


When looking at the remaining 2710 finally treated with PCI, we find that atorvastatin preloading was associated with a 28% reduction of combined end points, compared to placebo (p=0.02) and a reduction of 32% of MI risk (p=0.04), including a 58% reduction of unrelated MI.

Original title: Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial.

Reference: Berwanger O et al. JAMA. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....